MSH2 and cancer: Major differences in lifetime risks of cancer have been reported among MMR mutation carriers, with the highest risk attributed to the presence of a mutation in either MLH1 or MSH2. Cancers in families with an MSH6 pathogenic variant are usually diagnosed later and cancer risks are lower, with the exception of endometrial cancer 8, 9, 10, 11.